EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Corcept Therapeutics's enterprise value is $7,898.3 Mil.
Corcept Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $685.4 Mil. Therefore, Corcept Therapeutics's EV-to-Revenue for today is 11.52.
The historical rank and industry rank for Corcept Therapeutics's EV-to-Revenue or its related term are showing as below:
LTS:0I3Q'
s EV-to-Revenue Range Over the Past 10 Years
Min: 3.22 Med: 7.06 Max: 21.28
Current: 11.52
During the past 13 years, the highest EV-to-Revenue of Corcept Therapeutics was 21.28. The lowest was 3.22. And the median was 7.06.
LTS:0I3Q's EV-to-Revenue is ranked worse than 59.28% of 997
companies
in the Biotechnology industry
Industry Median: 7.39
vs LTS:0I3Q: 11.52
Corcept Therapeutics EV-to-Revenue Historical Data
The historical data trend for Corcept Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Corcept Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Corcept Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's EV-to-Revenue falls into.
Corcept Therapeutics's current Enterprise Value is $7,898.3 Mil.
Corcept Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $685.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics's share price for today is $77.2155.
Corcept Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.92.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Corcept Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0I3Q has been successfully added to your 